pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
AdCom · news · pharmadog
← back to AdCom
News · AdCom
209
stories
17h
FDA again turns back Capricor Duchenne cell therapy
biopharma dive
1d
Capricor’s regulatory odyssey for DMD cell therapy hits second FDA rejection
biospace
4d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
4d
White House yanks Overton nomination hours before committee vote
biospace
10d
Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears
biospace
10d
Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapy
biospace
11d
Capricor, NextCure shed light on recent layoffs as they gear up for approval decision, merger
fiercebiotech
11d
FDA's rare disease framework faces its first real test in Capricor’s DMD drug
biospace
12d
Update: FDA investigates Novartis' Zolgensma following 9 cases of tumors in treated patients
biospace
13d
FDA’s new rare disease framework aims to leverage patient voices for better innovation
biospace
15d
Moderna enjoys stable vaccine sales thanks to global COVID uptake
biospace
16d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
16d
Head of family physician group seeks ACIP 'guardrails'
endpoints
16d
Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
biospace
19d
UniQure gets an FDA decision date; Teva scraps brain drug study
biopharma dive
19d
FDA peptide policy risks undermining drug development and patient safety
biospace
19d
STAT+: Psilocybin’s lasting benefits prove elusive in mice
stat
19d
UniQure gets review date and adcomm; Inovio's stock surges after approval
endpoints
19d
FDA grants uniQure’s Huntington’s gene therapy priority review, teeing up ‘defining milestone’
fiercebiotech
19d
UniQure snags May Day decision date for Huntington’s gene therapy after arduous year
biospace
20d
Significant stock movers of October: Biohaven climbs, ArriVent dives
biospace
20d
Opinion: The economics of the U.S. health care system are broken
stat
20d
BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
biospace
23d
Opinion: How Congress can fix expert advisory committees
stat
24d
HHS clears compounding pharmacies to manufacture 6 unapproved peptides
biospace
24d
STAT+: HHS moves to allow compounding of some unapproved peptides
stat
24d
FDA’s rare disease framework aims to ‘stand the test of time’
fiercebiotech
Oct 22, 26
Biohaven’s previously rejected rare disease drug to get fresh FDA review
biopharma dive
Oct 22, 26
Biohaven shares pop as FDA accepts resubmission for ataxia drug with adcomm expected
biospace
Oct 19, 26
STAT+: The umpires getting rich off surprise medical bills, and MLB job lock
stat
← prev
page 1 of 7
next →